ONWARD Medical N.V., the neurotechnology company pioneering spinal cord stimulation therapies to restore movement, function, and independence, announces ...
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced a shared commitment with the Trump Administration to lower the cost...
Revolution Medicines, Inc., a global commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patie...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces a breakthrough in RF resection technology for hip with its new FLOW FLE...
Following the introduction of Invenia™ ABUS Prime at the Society of Breast Imaging Annual Symposium, the installation at BeSound in Los Angeles...
-- Company received communication from FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form...
Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipme...
Australian medtech investor Bioshore Ventures and US neurotechnology investor Jumpspace Ventures join Wellumio's oversubscribed pre-Series A round in the f...
Leica Biosystems, an operating company of Danaher (the "Company"), and a global leader in anatomic pathology solutions advancing precision cancer diagnosti...
Abcam, a Danaher company and a global provider of validated antibodies and assay solutions, and EpiCypher®, the leading provider of ChIC/CU...
-Thubrikar Aortic Valve, Inc. announced its partnership with MAC’s MEDICAL Group, a distributor of cardiovascular devices in Europe, and MAC&...
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the nextâ€...
Advanced NanoTherapies, Inc. (ANT), a clinical-stage medtech company dedicated to improving outcomes for patients with coronary and peripheral artery dis...
Compared with patients receiving hormone therapy alone, patients were nine times more likely to havelittle to no cancer remaining in the prostate after s...
© 2026 Biopharma Boardroom. All Rights Reserved.
